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Abstract:   
 
The Continual Reassessment Method (CRM) has gained popularity since its proposal by O’Quigley 
et al. [1].  Many variations have been published and discussed in the statistical literature, but there 
has been little attention to making the design considerations accessible to non-statisticians.  As a 
result, some clinicians or reviewers of clinical trials tend to be wary of the CRM due to safety 
concerns.  This paper presents the CRM in a non-technical way, describing the original CRM with 
some of its modified versions.  It also describes the specifications that define a CRM design, along 
with two simulated examples of CRMs for illustration.   
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I.  Introduction 
 
The Continual Reassessment Method, developed by O’Quigley et al. [1], is a study design for dose 
finding (sometimes called Phase I) studies.   Its proponents believe it to be superior to traditional 
dose-escalation designs because it “learns” from information gained at early time points in the 
study, it is less likely to treat patients at toxic doses and more likely to treat patients at efficacious 
doses.  Many of its critics have concerns about its safety, worrying that escalation occurs too 
quickly and that patients may be treated at unsafe doses based on reliance on a mathematical 
model [2-4].  These concerns are largely unfounded.  Current implementations of the CRM include 
criteria that disallow steep dose escalations and include the standard safety considerations of more 
traditional designs.    
 
Many of the criticisms are in fact not criticisms that are specific to the CRM:  they are applicable to 
most dose finding studies which treat 4 or fewer patients per dose level.   Trialists often feel 
comfortable applying the standard “3+3” design (see Box 1), assuming that it is well-understood 
and safe [5].    However, the “3+3” design is in general no safer than the CRM or many other Phase 
I studies.  Its main comfort-level stems from its common use.  Most phase I studies tend to treat 
relatively few (i.e. 4 or fewer) patients at each of a small number of dose levels.  As such, the 
certainty with which dose escalations, de-escalations, and the choices of dose levels are made tend 
to be poor.  The “3+3” and other similar designs suffer from another flaw which is that users of this 
design often think that the chosen MTD is the dose which is most likely to have a toxicity rate of 
approximately 33%.  This is not the case.  In general, the true toxicity rate of the MTD in these 
studies will tend to be less than 33%, but toxicity rate estimation will be very imprecise given the 
few number of patients in the trial and at each dose level.  However, in CRM-type designs, the 
toxicity rate is made explicit and the optimal dose (ergo, the MTD) is the dose that is estimated to 
be the one closest to achieving the desired toxicity rate.   
 
One of the reasons that the CRM has not been more widely adopted is that it is not clearly 
understood.  It has mathematical and statistical complexities that make it relatively difficult for 
many to understand.  The goal of this paper is to explain the CRM, and some of its varieties, to the 
non-statistical reader.  This does not imply that the CRM can be implemented without the 
consultation of a statistician:  it is imperative that a statistician be involved in CRM trial design 
and CRM trial conduct.  However, it is also imperative that (1) clinical investigators planning dose 
finding trials understand the CRM and how it might be an appropriate choice for their studies, and 
(2) members of institutional review boards and scientific review committees understand how the 
CRM works and compares to traditional designs in terms of safety and ethical considerations for 
patients.  Note that in this paper, we focus on the dose-toxicity relationships.  However, the CRM is 
more general, such that dose-efficacy relationships can also be explored using the CRM in a similar 
manner.    
 
The paper is organized as follows.  We provide some historical background of the CRM in section 
II.  In section III, the steps of defining a CRM design are described.  Section IV provides examples, 
including some practical issues in CRM trial conduct.  The last section is a brief discussion. 
 
II.  Describing the CRM 
 
II.a. The original CRM, introduced by O’Quigley et al. 1990 
 
The CRM was first introduced by O’Quigley et al. and drew much attention from the biostatistical 
community [1].   The general idea behind the original CRM was that an a priori dose-toxicity curve 
Hosted by The Berkeley Electronic Press
(DTC) was assumed and a desired toxicity rate was chosen.  The estimated DTC was updated after 
each patients’ toxicity outcome was observed, so that each patient’s dose was based on information 
about how previous patients tolerated the treatment.  For example, in figure 1, an a priori DTC is 
shown by the solid line where we can see that at the lowest dose level (dose level = 1), the 
probability of a dose-limiting toxicity (i.e. ,  DLT) is very close to 0.  As dose level increases, the 
chance of DLTs increases.    If we assume that the desired level of toxicity is 0.40 (meaning that it 
would be acceptable if 40% of patients had a DLT), then, according to this dose-toxicity curve, dose 
level 4 would be the optimal dose.  So, assume that the solid curve in figure 1 is chosen a priori to 
represent our best guess at the dose-toxicity relationship.  Then, the first patient in the trial would 
receive dose level 4 and would be observed for a DLT.    However, if we were instead to assume that 
the dashed curve were our a priori guess about the dose toxicity curve, we would be more inclined 
to choose dose level 2 as the starting dose (i.e. the dose associated with 40% toxicity).  An 
important point about the dose-toxicity curves shown in figure 1 is that they are based on 
mathematical models.  Specifically, the curves shown in figure 1 are logistic curves which take 
values between zero and one and are monotonically related to dose.   The logistic curves shown in 
figure 1 are “two-parameter” logistic models:  each has a slope and scaling constant (like an 
intercept) which define it.   
 
After the first patient has been treated at the dose chosen using the a priori DTC, whether or not 
s/he experienced a DLT is recorded.  This information is then “combined” with the a priori dose-
toxicity curve to get a better estimate of the true curve.  In other words, we are updating our 
knowledge about the dose-toxicity relationship using the data that we accumulated from the first 
patient.  The specifics of how this updating occurs will be described later in section IV.  When we 
update our curve, we get a new estimated dose response curve.  It likely looks much like our a 
priori curve, but is slightly shifted up or down depending on whether or not the first patient 
experienced a DLT.  Updating with just one datapoint might not seem like much information, but 
as the number of patients accumulates, the dose-toxicity curve becomes estimated almost 
exclusively from the observed data and may look very little like the a priori curve that we began 
with.   How much the curve changes will depend on how much weight we want to put on our a 
priori curve. 
  
For those familiar with Bayesian statistics, the a priori curve represents our prior estimate of dose 
response and the accumulating information from patients represents our likelihood function.  The 
resulting estimate of the dose-toxicity curve is our posterior estimate.   The strength of the prior 
can be determined based on the precision parameters in the prior distributions chosen for the 
slope and scaling constant. 
 
Using our updated dose-toxicity curve, we find what is now our best estimate of the optimal dose.  
By our earlier definition, this is the dose associated with a toxicity rate of 0.40.  So, as before, we 
can graph our updated dose-toxicity model and find the dose that is associated with  
an estimated toxicity rate of 0.40.  On figure 1, the dotted lines represent the two ways that we 
could have updated our curve: (1) the first patient could have experienced a DLT, in which case our 
updated DTC would fall slightly to the left of the solid a priori curve; or (2) the first patient could 
have not had a DLT, in which case the updated DTC falls slightly to the right of the a priori curve.   
If the former had occurred, the next patient would be treated at a dose of 3.9 and if the latter 
occurred at a dose of 4.2.  The trial continues in this fashion:  after each patient is treated, we re-
estimate the DTC and treat the next patient at our new best estimate of the optimal dose.  Patients 
continue to be treated until some level of certainty is achieved (stopping rules will be discussed in 
more detail in the next section).   This is the general paradigm of O’Quigley et al’s CRM. 
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This design grew criticism because of safety concerns.  First, it was felt that large dose escalation 
steps might occur, subjecting individual patients to doses that were likely to cause DLTs.  Second, 
beginning the CRM at the level deemed most appropriate by the a priori curve seemed to put 
patients in danger of exposure to toxic levels of the treatment:  in many cases, the a priori curve 
was chosen with great uncertainty.  The first of these criticisms of the original CRM has some 
merit.  However, it can be argued that the second concern is not reasonable when comparing the 
CRM to other phase I designs which choose the initial dose level in much the same fashion as the 
CRM.  Even so, as a result of both these concerns, several years later, modified CRMs were 
introduced.   
 
Box 1:  The standard “3+3” dose escalation design. 
 A. At each dose level, treat 3 patients beginning with dose level 1.  Escalate to the next dose 
  level or de-escalate to the previous dose according to the following rules: 
  1.   If 0 of 3 patients have a dose limiting toxicity (DLT), increase dose to next level. 
  2.  If 2 or more patients has a DLT, decrease dose to previous level.* 
  3.  If 1 of 3 patients has a DLT, treat 3 more patients at current dose level. 
   a. If 1 of 6 has DLT, increase to next dose level. 
   b. If 2 or more of 6 have DLT, decrease to previous level.   
  4.  If a dose has de-escalated to previous level: 
   a. If only 3 had been treated at the previous level, enroll 3 more patients.   
   b. If 6 have already been treated at the previous level, stop study and declare 
    it the MTD. 
 B.  The maximum tolerated dose (MTD) is defined as the largest dose for which 1 or fewer 
  DLTs occurred. 
 C.  Escalation never occurs to a dose at which 2 or more DLTs have already occurred. 
 
 * if de-escalation occurs at the first dose level, then the study should be discontinued. 
 
II.b. Revised forms of the CRM 
 
In the mid-1990’s several variants of the CRM were introduced, addressing some of the safety 
concerns of the O’Quigley et al.’s proposed design.  Goodman et al.  retained the same general 
ideas of the CRM, with some modifications, calling the revised design the “Modified CRM” (see 
Box 2) [2].   The general idea is to begin the study like a “3+3” (or similar variant like a “2+2”) and 
then switch to a CRM-type escalation procedure once the first DLT is observed.  As such, the 
modified CRM requires a set of pre-specified doses in which to escalate.   Once the CRM “kicks in,” 
the modified CRM has some other key differences from the O’Quigley’s version.  First, the 
mathematical model is not solely responsible for determining the dose increases:  dose increases 
are restricted by the pre-defined dose levels (i.e., large dose escalations are not permitted).  A 
second main difference is that the modified CRM generally employs cohorts of size 2 or 3, unlike 
O’Quigley et al.’s size of 1.   In practice, when there are no DLTs seen in a CRM design, it actually 
progresses much like the standard ‘3+3’.  Additionally, when using the modified CRM, one of the 
major differences is that we do not use the a priori dose curve to choose our initial dose level:  we 
use the lowest dose level under consideration.   
 
Box 2: Goodman et al.’s “Modified CRM”  
  1.  Pre-define dose levels for escalation as if for a “3+3” design. 
  2.  Always start at the lowest dose level under consideration (i.e. in Figure 1, this  
   would be dose level 1). 
  3.  Enroll 1, 2, or 3 patients at each prescribed cohort (as opposed to only 1 per  
   cohort).  
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  4.  Proceed as a standard dose escalation design in the absence of DLTs  
  5.  Any given dose escalation cannot increase by more than one level, although dose 
   de-escalations can be large. 
  6.  Stop at a fixed a priori sample size. 
 
Another variant was proposed at the same time by Möller [6].  Her motivation for revising the 
CRM stemmed from the idea that not a large enough range of doses tend to be considered in 
standard dose escalation designs, and so her design explores many doses and starts at a low dose 
level.  Möller proposed two different revised CRMs.  The first is the ‘extended’ CRM, where the 
design is split into two stages.  In the first stage, the standard phase I ‘3+3’ type of approach is 
used until one DLT is observed.  Once a DLT is observed, the study enters the second stage where 
the design switches to a CRM where all of the information from stage 1 is included for estimating 
the DTC.   In practice, this is very similar to Goodman et al.’s design described above.  Möller’s 
second proposed revision (the ‘restricted’ CRM) simply prevented escalations from exceeding one 
dose level—another facet of Goodman et al.’s  modified CRM.  The conclusions that Möller drew in 
evaluating these designs (i.e., the original CRM by O’Quigley, the restricted, and the extended) 
were that the original CRM tended to treat too many patients at high doses, the restricted CRM 
took many more patients to complete than the other two designs, but that all three provided 
unbiased estimates of the MTD.   
 
Piantadosi et al. [7] proposed yet another similar variant of the CRM, which we will call the 
‘practical’ CRM.  The differences in Piantadosi et al.’s version are described in detail in Box 3.   
 
Box 3:  Piantadosi et al.’s ‘practical’ CRM. 
 1.  Study preclinical information about toxicities. 
 2.  Quantify clinical intuition about dose-toxicity by choosing dose level that would be  
  guessed to incur low (e.g. 10%) toxicity and level that would be guessed to incur  
  high (e.g. 90%) toxicity rate. 
 3.  Estimate/draw the DTC assuming that the DTC passes through the dose-toxicity points 
  described in 2. above. 
 4.  Use the DTC curve to find the target dose for the desired toxicity level. 
 5.  Treat 3 (or more) patients at the target dose. 
 6.  Re-estimate the DTC based on the toxicity outcomes of the treated patients. 
 7.  Revise estimate of the dose associated with high toxicity (from step 2 above).   
 8.  Repeat steps 3-6 until target dose changes by less than 10% or meets another   
  appropriate criterion for stopping. 
 9.  Use target dose for future trials. 
 
Because this is paper is not meant to describe every variant of the CRM that has been proposed, we 
refer the reader to other sources for more description of other CRMs [5, 8-13]. 
 
III.   Defining a CRM design 
 
There are two general properties that we commonly assume when defining CRM trials.  We begin 
with them and then discuss how to go about defining a CRM trial.  First, we assume that the DLTs 
are binary:  patients either experience a DLT or they do not.   If a patient experiences a toxicity, it 
is coded using the value 1, and if he does not, it is coded using the value 0.   Second, we assume 
that the DTC curve is an increasing function of dose.  In other words, as dose increases, the 
probability of toxicity increases.   
 
IIIa.  Choosing a dose-response model 
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One of the most important and often the most difficult part of designing a CRM is choosing the 
“functional form” (i.e. mathematical model) of the dose toxicity curve.  It is important that a 
trained statistician be involved in choosing the mathematical model.  And, it is critical that the 
statistician and clinicians both look at plots similar to those shown in figure 2 to have a clear 
understanding of the mathematical model that is being proposed.  Reviewers of these trials might 
want to require visual displays of the proposed model—otherwise it can be difficult to discern the 
assumed relationship between dose and toxicity.  There are a variety of models to choose from, but 
there are relatively few that tend to be used in practice and they fall into two categories:  one 
parameter models, and two-parameter models.  One parameter models, as their name implies, are 
somewhat simpler yet more restrictive than two-parameter models.  The benefit of using one 
parameter models is that they require less information (i.e. fewer patients) to get a more precise 
estimate of the DTC.  However, because they are more restrictive, they may not be flexible enough 
to accurately depict the true dose-toxicity relationship.   
 
As part of the design of a CRM, we need to choose a model a priori which we deem consistent with 
our expectation of the relationship between dose and toxicity.  Examples of four different 
functional forms are shown in Figure 2.  The DTCs shown in figure 2A are based on the hyberbolic 
tangent function, as suggested by O’Quigley et al. [1].  Technically this means that,  
  
    p
d= +


tanh( ) )1
2
α
 
 
where p is the probability of toxicity and d is the dose.  The unknown parameter of interest in the 
model is α (i.e., Greek letter “alpha”).  In figure 2A, the curves each have a different value of α:  the 
smaller the α, the higher the DTC in this case.  When choosing the functional form for our CRM, 
we do not need to determine what we think α will be:  just that we think that a curve from this 
“family” of curves is an appropriate way to model the relationship between dose and toxicity.  The 
parameter α is estimated as part of the CRM:  we use data about toxicity seen during the trial to 
estimate which α is most appropriate.  In the case of figure 2A, if the toxicity associated with the 
treatment is relatively high, a small value of α will be estimated.  However, if the toxicity is low, 
then the estimated value of α will be large. 
 
The hyperbolic tangent model is just one way that we can quantify the relationship between dose 
and toxicity.  Another common model is a one-parameter logistic model as used by Goodman et al. 
[2], for which examples are shown in figures 2B and 2C.  The parameter α in this model 
determines the slope (and height) of the curve:  the flattest of the curves has the lowest value of α 
and as the value of α increases, the DTC curve becomes steeper.   There are several different ways 
in which a one-parameter logistic model can be parameterized.  One of the key design choices in 
the one-parameter logistic CRM is that a constraint must be imposed such that there must be one 
dose level at which all of the curves under consideration (i.e. for all levels of α) have the same 
assumed probability of toxicity.  In figure 2B, we can see that all of the DTCs converge at a 
probability of toxicity at 0.05 at dose level 1.  In figure 2c, we use a different parameterization (or 
different mapping of doses) so that all curves pass through the toxicity rate of 0.90 at dose level 
6.5.  For trials where the primary interest is in toxicity, we would be interested in models such as 
those seen in 2c because we are interested in doses with low probability of toxicity (i.e. <0.40):  in 
figure 2c, there is quite a lot of variation in the DTCs in the 0.10 to 0.30 range.  However, if efficacy 
were the goal then we would want to make sure that the curves we were considering had large 
variability for high probability values (for efficacy, we usually want to find doses with high 
probabilities):  in this case, figure 2B would be more appealing due to its flexibility in the range of 
0.7 to 1.0.  In general, when using a one-parameter logistic model, we will want to choose the dose 
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at which the curves converge to be either a very high dose (for toxicity-related trials) or a very low 
dose (for efficacy-related trials).   This is because we do not expect to be iterating at values near the 
convergence point where there is little flexibility in the model.   For more details of how to 
parameterize the a one-parameter logistic model, see Goodman et al. [2].  
 
The two parameter logistic model, as is used by Piantadosi et al. [7], is a more attractive choice 
than the one parameter logistic model because both the slope (α) and intercept are estimated as 
part of the CRM.  We are not constrained to only consider models which all converge at one dose 
level:  estimating the intercept as part of the model allows us this flexibility.  As mentioned above, 
the estimate of the DTC curve based on the two parameter model may not be as precise for a given 
sample size, but the model is more robust than the one-parameter model.  In other words, it is less 
subject to “model-misspecification” as compared to the one-parameter model.  However, allowing 
for the flexibility of two parameters, the parameter estimates may be unstable.  Some models based 
on the two-parameter logistic function are shown in figure 2D.  Notice that the curves take a 
variety of shapes, with varying slopes and intercepts.  
 
The models shown in Figure 2 should provide some options for choosing your functional form.  An 
example of another mathematical model recently implemented that is more ad hoc can be found in 
Mathew et al. [14].   
 
IIIb.  The spacing of the doses 
In figures 2A through D, the doses are labeled as dose levels 1 through 7.  These are simply 
“names” for dose levels and the actual doses corresponding to these levels need to be chosen by the 
clinical investigator.  For example, in many clinical trials the ‘modified Fibonacci’ sequence is used 
to choose doses, where the increments are 2, 1.67, 1.5, 1.4, 1.33, 1.33, …, 1.33.  Assume that we 
define dose level 1 as 100mg.  Using the modified Fibonacci sequence, the next dose levels would 
be 200mg (2x100), 330mg (200x1.67), 500mg (330x1.5), and so on.  We could “map” these doses 
to the corresponding dose levels such as those in figure 2.    
 
But, the modified Fibonacci is not the only choice and it is certainly not necessarily the correct 
choice.  For example, instead of using the modified Fibonacci, it might be sensible to use a log scale 
for the horizontal axis (e.g. dose level 1 = 100mg, dose level 2 = 1000mg, dose level 3 = 10000mg, 
etc.) or to make dose increments a constant increase (e.g. dose level 1 = 100mg, dose level 2 = 200 
mg, dose level 3 = 300 mg, etc.).    The increments chosen should depend on the preclinical 
information.   
 
The easiest and most common way to solve this problem is to determine how you would choose 
your doses if you were to do a standard ‘3+3’ or similar design.  Depending on which version of the 
CRM you are using (as described in section II), you will often need to do this anyway.  In most 
cases, based on preclinical or other preliminary data, the clinical investigator develops a series of 
dose levels that increase in increments in a predictable fashion (e.g. modified Fibonacci, log 
increases, etc.).   These dose levels can then be mapped to the horizontal axis of the DTC plot. 
 
IIIc.  Number of patients per dose 
As is stated above, the original CRM uses just one patient per dose level.  However, it is quite 
common to see versions of CRMs implemented with more patients per dose level, given concerns 
over escalating too quickly.  The number of patients per dose should depend on several factors, 
including (a) how conservative you would like to be in terms of quickly escalating, (b) how many 
patients are feasible, and (c) how precise you would like to be in your estimation of the dose 
toxicity relationship.  The more patients per dose, the more information you will have about the 
dose- toxicity relationship.  But, obviously, a trial with more patients per dose will take longer to 
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complete and will be more costly.   Despite the trade-off between the precision and sample size, the 
safety of the patients should be the over-riding concern.  As such, with precision and sample size as 
secondary considerations, the number of patients per cohort should be largely determined with 
regard to safety. 
 
IIId. Target toxicity or response rate 
One of the key study design parameters is the target toxicity rate (or response level, if efficacy is 
the outcome).  In oncology trials of chemotherapy or other treatments that are given over a 
relatively short time period but have the potential for serious possibly life-threatening side effects, 
the target rate is often set between 0.20 and 0.30.  In situations where the treatment is given as a 
long-term regimen, the target toxicity rate is likely to be less (in the range of 0.10 to 0.20).  Again, 
there is not a standard that is used:  the investigator should carefully consider how serious, 
tolerable and treatable the toxicities are for the treatment of interest.   If efficacy is the goal of the 
study, then clearly we would want to set a relatively high threshold for our target rate depending 
on the nature of the response desired.  If we are looking for clinical response, the rate will depend 
on the disease being studied and might range anywhere from 0.30 to .80.  If biologic or 
pharmacologic response is of interest, setting a higher efficacy rate might be more practical, such 
as a rate of 0.80 or 0.90.  Setting an efficacy level as high as 1.0, while seemingly appealing, is not 
practical and should generally not be used.   
 
IIIe.  Prior or design in absence of toxicities 
In the original formulation of the CRM and in some of the modified versions, an a priori (or 
“prior”) DTC was assumed.   As is mentioned above, this a priori assumption is combined with the 
observed toxicity data to determine the dose at the next cohort of patients.  The a priori DTC is a 
critical component of the CRM:  without some assumption of the shape of the DTC, when we have 
not observed any toxicities, we cannot make any guess about what dose would incur toxicities at 
the desired rate.  Imagine that at dose levels 1, 2, and 3 we see zero toxicities in a total of nine 
patients (three per cohort).   This tells us, based on the observed data, that we estimate 0% toxicity 
at each of the three cohorts.  And, it tells us nothing about at what dose we would expect the DTC 
to increase, or how quickly we would expect it to increase.  This is critical information for choosing 
the subsequent dose.  In the CRM, we get some information when the increase is expected to occur 
(and how quickly) from the a priori DTC.  In a case where we have seen no toxicities, without the a 
priori DTC, we are not able to estimate the dose for the next cohort.  
 
As an alternative to using an a priori curve, Goodman et al. [2] suggested beginning by starting 
with a ‘3+3’ design, where a fixed number of doses are chosen and each of the doses has a defined 
quantity.  In this case, we follow the ‘3+3’ design until the first DLT is observed.  At this point, the 
design switches to a CRM.   Since one DLT has been observed, we have enough information for an 
estimate of the DTC without needing a formal a priori DTC.  One of the benefits of this approach is 
that it is much more natural to many clinical investigators who are comfortable with choosing a set 
of doses to consider in a standard phase I trial than defining an a priori curve.  Additionally, in this 
approach, once a DLT occurs, only the observed data is used for escalating:  the chosen doses are 
only used to limit the amount of escalation, whereas the a priori DTC information is included at 
every iteration of the CRM. 
 
III.  Stopping and sample size 
There are several commonly used stopping rules for CRM designs.    In many cases, a fixed number 
of patients is decided at the onset of the trial and the CRM continues until the total sample size is 
reached, regardless of the number of doses considered and the number of patients treated per 
dose.  This is particularly appropriate when dose levels can be continuous as opposed to discrete.  
This might be the case when the treatment is given as an infusion where the amount of drug given 
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can be quantified to very small increments.  This would not be the case when the treatment under 
consideration comes in pill form where the pills are of a fixed dosage and so doses can only be 
given in pill-sized increments .  Another approach that is more appropriate for discrete dose 
settings is to stop the trial once a fixed number of patients have been treated at any dose.  For 
example, assume that in a trial, cohorts of 2 are used and the CRM has seemed to “settle” around a 
particular dose: it has treated 10 patients at that dose, and it recommends the same dose again for 
the next cohort.  At this point, the trial would end and that dose would be considered the MTD.   
This is a difficult endpoint to work with when you allow for continuous dose levels, but it can be 
done.  For example, Piantadosi et al.  suggest stopping with the target dose changes by less than 
10% [7].   Ishizuka and Ohasi suggest another stopping rule that depends on the precision of the 
DLT curve [10].  More discussion of stopping rules for CRMs is provided by Zohar and Chevret [15] 
and O’Quigley and Reiner [16]. 
 
IV.  Two examples of the CRM 
 
A.  Example 1.  In this design, we are using cohorts of size 2 and have a target DLT rate of 0.25.   As 
in Goodman’s modified CRM, we will begin with a standard escalation design until toxicity is 
observed and then we will allow the CRM to “kick in.”  We will assume discrete doses such that 
doses can be given in 50mg increments.  The probability model that we will use is the hyperbolic 
tangent where the true doses are mapped to values are shown in Table 1. 
 
In this simulated example, no toxicities were seen in dose levels 1, 2, and 3.  At dose level 4 
(400mg), there was 1 toxicity seen out of two patients.   At this point the CRM is implemented, as 
is shown in Table 2.   Using all of the information collected up through this cohort of patients, we 
can find the α value that is most consistent the data observed.  In this example, the estimated α for 
of our model based on the toxicity information observed is 1.78.  With this estimated α of 1.78, the 
most appropriate dose (i.e. the one that is our best estimate of the dose for a DLT rate of 0.25) is 
350mg (which is shown as the dose for cohort 5).   The CRM continues in this way.  At the dose of 
350, no toxicities are seen and our estimated α is 2.24, suggesting in increase in dose to 450.   
 
The CRM continues to iterate until our stopping rule is achieved.  In this study, the stopping rule 
was defined such that the trial terminates when 10 patients have been treated at a particular dose 
and the next cohort of the CRM would give the same dose.  In the example above, after the 11th 
iteration, 10 patients have been treated at a dose of 450mg, and (if the CRM were to continue), the 
chosen dose for the next cohort is 450mg.   
 
A graphical display of the iterations of the study (i.e., cohorts 4 through 15) is shown in figure 3.   
In this example, the CRM quickly converges to the area between 350 and 550mg doses and 
remains there for all of the cohorts after the CRM part of the study begins.  So, there is movement 
in cohorts 4 through 15 (as can be seen in the table above), but it is confined to a relatively narrow 
range as compared to the initial range of doses under consideration (50mg to 800mg).  In cohorts 
7 through 15, the plots in figure 2 focus only on range of doses 350 through 550 to demonstrate 
how the CRM iterates to find the CRM, but it is important to point out that all of the toxicity 
information that is accumulated from all cohorts is used to estimate the DTC at every iteration of 
the CRM. 
 
Based on the observed data, we can tabulate the toxicities observed at each of the doses, as shown 
in table 3.  At the chosen dose (450mg), our estimated rate of DLTs  given the observed data is 
23%. 
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Example 2:  The second example uses the method described in Piantadosi et al. (1998), where 
initial estimates of doses that produce high and low rates of DLTs are used to choose the first dose.  
We will assume that at 200 mg and 3000mg the rates of DLT are 10% and 90%, respectively.   Our 
target DLT rate is 0.30.  A two-parameter logistic model will be used to describe the relationship 
between DLT rate and dose.  Our stopping rule is such that we will stop the trial when a total of 30 
patients have been treated.   With three patients per cohort, we will perform ten iterations of the 
CRM.   In this example, we will assume that doses need not be discrete:  dose to the nearest 1 mg 
can be accommodated (this is common when the treatment of interest is given as an infusion or the 
pharmacy can make capsules with drug levels that are very precise).   Several safety mechanisms 
are also put into place:  dose escalation cannot escalate by more than 400mg.   The data presented 
in this example are generated based on a true model of toxicity:  that is, the DLT data has been 
generated from a particular DTC curve.   
 
Using our initial estimates of 10% DLT rate at 200mg and 90% DLT rate at 3000mg, we can 
estimate the best fitting logistic model by choosing the slope (β) and d50 level such that the model 
passes through these two points.  In Figure 4A, our initial estimate of the DTC curve is shown via a 
dotted line.  Using our initial estimate of the DTC curve, we find that the initial dose of 1060 mg is 
most consistent with our DLT rate of 0.30.  And so, the first 3 patients are entered at a dose of 
1060mg.  Of these three patients, one has a DLT.  Using this information, we recalculate the DTC 
and estimate the dose that is predicted to cause DLTs in 30% of patients.  This continues until 30 
patients (i.e., ten cohorts) have been treated.   
 
Consider Figure 4A, which shows our initial estimate of the DTC before observing any data (dotted 
line), the estimated DTC based on the DLTs of the 30 patients in the study (solid line), and the true 
DTC from which the DLTs were simulated.  In figure 4A, we see that even though our initial 
estimate was not very accurate, our estimate of the DTC based on 30 patients is very accurate, 
falling almost directly on top of the true DTC.  However, this does not always occur in practice.  
Figures 4B, 4C, and 4D show three other possible estimated DTCs.  In figure 4B, we see that the 
CRM has predicted the correct dose (or very close to it), but the actual shape of the curve is not 
very consistent with the shape of the true DTC.  Figures 4C and 4D tend to under and over-
estimate the dose, respectively.  This is included to remind the investigator that, just like other 
Phase I designs, the CRM is not perfect:  it will not find the correct dose everytime.   However, 
there are steps one can take to increase the likelihood that the correct dose (or a dose very close to 
the correct dose) will be chosen. 
 
Table 4 shows how precise the design in example 2 is (i.e. a total of 30 patients with cohorts of size 
3), assuming the true DTC as shown in Figure 4A compared to two similar trials.  Note that based 
on the true DTC and the target DLT rate of 0.30, the ideal dose is 1656 mg.  The numbers in the 
table are based on simulations of each design (1000 per design).  For each simulation, the 
“recommended dose” was recorded.  These recommended doses for each design were then 
summarized to describe how accurate each design is in choosing an appropriate dose.  Notice that 
designs 2 and 3 differ from design 1 in that both are larger (sample sizes are 50 and 60, 
respectively, versus a sample size of only 30 in design 1).   Design 2 has the same number of 
cohorts as design 1, but there are five patients treated at each cohort versus only three as in design 
1.   In design 3, cohorts size is the same as in design 1, but there are twice as many cohorts (twenty 
versus ten).    By increasing the sample size, we see that we get dose estimates closer to the true 
dose.  For example, in design 1, 80% of trials recommend a dose within 400mg of the ideal dose, 
whereas in designs 2 and 3, 89% and 91% of trials recommend a dose within 400mg of the ideal.  
Four-hundred mg might seem like a large difference, but in looking at the DLT rates, most of the 
trials in all of the designs do not tend to overestimate the dose significantly in terms of DLT rate.   
For design 1, only 9% of trials recommend doses with a greater than 40% DLT rate, and for the 
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larger trials, only about 5% recommend dose with DLT rate greater than 40%.   It is extremely rare 
for any of these designs to recommend a dose that has a DLT rate greater than 50% or less than 
10%.  Based on table 4, we can conclude that precision of our estimate will increase if we are to 
choose a larger sample size (either by increasing the number of cohorts or by increasing the 
number of patients per cohort).   However, as cannot be seen in this example, the amount of 
additional information that you will gain by increasing the sample size will depend in large part on 
the shape of the true DTC curve:  here we are only considering one scenario. 
 
   V.  Discussion 
 
The CRM is a novel and statistically appealing design for choosing an appropriate dose from a 
Phase I study.  Some of its benefits include the ability to choose the desired toxicity level, a 
quantification of the accuracy of the dose in relation to the desired toxicity level, and its efficiency 
for treating patients at doses near to the optimal dose.  In the past, it has been confusing to many 
clinical investigators because of its reliance on mathematical formulas for determining dose levels 
during the trial.   For those not familiar with maximizing likelihood functions, the CRM should not 
be out of reach:  the principles which underlie it are logical and (to some extent) need not be 
complicated by a lack of understanding of probability models.  The goal of this article was to make 
the CRM accessible to those interested in applying or understanding it and minimizing the reliance 
on mathematics.  As a result, some features of the CRM have been glossed over:  this is not for a 
lack of appreciation of the complexity of the model, but instead for the purpose of bringing the 
CRM to the attention of a broader audience than it may have previously appealed to.   
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Table 1:  Predefined dose levels for example 1.   
 
DoseLevel Dose Mapped value 
1 50mg -1.5 
2 100mg -1.0 
3 200mg -0.5 
4 400mg 0 
5 800mg 0.5 
 
 
 
 
 
 
Table 2:  Progression of example 1.  Cohort sizes are two.  One patient experiences DLT in cohort 4, 
at which point the CRM kicks in, the α parameter is estimated, and the doses for the remaining 
cohorts are determined by the CRM.   
 
 
Cohort Dose Outcomes 
(0=no DLT, 
1=DLT) 
Estimated α 
1 50 0 0 -- 
2 100 0 0  -- 
3 200 0 0  -- 
4 400 0 1 1.78 
5 350 0 0 2.24 
6 450 0 0 2.74 
7 550 1 0 2.40 
8 450 0 0 2.72 
9 500 0 0 3.03 
10 550 1 1 2.29 
11 450 0 1 2.11 
12 400 0 0 2.27 
13 450 1 0 2.13 
14 400 0 0 2.26 
15 450 0 0 2.39 
16 450 STOP  
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Table 3:  Summary of results of example 1.   
 
    DOSE     
 50 100 200 350 400 450 500 550 
No DLT 2 2 2 2 5 8 2 1 
DLT 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (17%) 2 (25%) 0 (0%) 3 (75%) 
Predicted Rate of 
DLTs 
 
<1% 
 
<1% 
 
4% 
 
14% 
 
19% 
 
23% 
 
27% 
 
32% 
 
 
 
 
 
 
Table 4.  Characteristics of three CRMs of varying size with the same true model of dose-toxicity.   
Results are based on 1000 simulated trials for each design. 
 
 Design 1 
(example 2) 
Design 2 Design 3 
Total sample size 30 50 60 
Patients per cohort 3 5 3 
Number of cohorts 10 10 20 
% of trials with recommended dose within 250mg of 
true dose (1656mg) 
58% 69% 72% 
% of trials with recommended dose within 400mg of 
true dose (1656mg) 
80% 89% 91% 
% of trials with recommended dose DLT rate of >40% 9% 6% 5% 
% of trials with recommended dose DLT rate of >50% 0.5% 0.4% 0.4% 
% of trials with recommended dose DLT rate of <20% 13% 6% 6% 
% of trials with recommended dose DLT rate of <10% 0% 0% 0% 
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Figure 1:  Dose-toxicity curves.  Solid line and dashed line represent two different choices 
for a priori DTCs.  The dotted lines represent updates to the solid a priori DTC after 
patient data has been observed.    
 
 
http://biostats.bepress.com/jhubiostat/paper74
Figure 2:  Four different mathematical models that could be used for the CRM.  A:  
hyberbolic tangent model. B:  one-parameter logistic model with constant value for d5 
(i.e. all curves impose the constraint that the probability of toxicity at dose level 1 is 
0.05).  C: one-parameter logistic model with different mapping of doses with constant 
value for d90 (such that all curves impose the constraint that at dose level 6.5 the 
probability of toxicity is 0.90).  D:  two-parameter logistic model.  
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Figure 3:  Demonstration of the CRM in example 1.  At cohort 4, the first DLT occurs and 
the CRM kicks in.  For each cohort, the accumulated toxicity information up to and 
including that cohort is used for estimating the value of α for the next cohort.  In cohorts 
7 through 15, the plots below focus on just the dose range of 350mg to 550mg to 
illustrated the movement of the modified CRM. 
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Figure 4.   True DTC is dashed line, estimated DTC is solid line, and initial estimate of 
DTC is dotted line.  A:  Accurate estimation of the true DTC and dose, B:  accurate 
estimation of dose, C:  underestimate of dose and poor estimation of DTC, D: 
overestimate of dose and poor estimation of DTC.  
 
A 
 
B 
 
 
C 
 
D 
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